Avian antibodies (IgY) targeting spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit receptor binding and viral replication.
Chad ArtmanKyle D BrumfieldSahil KhannaJulius G GoeppPublished in: PloS one (2021)
In this proof-of-concept study we showed that avian immunoglobulins (IgY) raised against a key virulence factor of the SARS-CoV-2 virus successfully inhibited the critical initial adhesion of viral spike glycoproteins to human ACE2 protein receptors and inhibited viral replication in vitro, in a short period using only two laying hens. We conclude that production of large amounts of IgY inhibiting viral binding and replication of SARS-CoV-2 is feasible, and that incorporation of this or similar material into an intranasal spray and/or other mucosal protecting products may be effective at reducing infection and spread of COVID-19.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- binding protein
- staphylococcus aureus
- signaling pathway
- endothelial cells
- pseudomonas aeruginosa
- biofilm formation
- coronavirus disease
- angiotensin ii
- angiotensin converting enzyme
- cancer therapy
- induced pluripotent stem cells
- protein protein
- cell migration
- pluripotent stem cells